08.11.2022 22:01:00
|
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
SAN DIEGO, Nov. 8, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor conferences:
- Kevin Gorman, Chief Executive Officer, Matt Abernethy, Chief Financial Officer, and Kyle Gano, Chief Business Development and Strategy Officer, will present at the Jefferies London Healthcare Conference at 1:30 p.m. Greenwich Mean Time (8:30 a.m. Eastern Time) on Tuesday, Nov. 15, 2022 in London.
- Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, will present at the 5th Annual Evercore HealthCONx Virtual Conference at 12:35 p.m. Eastern Time on Thursday, Dec. 1, 2022.
The live presentations will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com. A replay of the presentations will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis* and uterine fibroids*, as well as over a dozen mid-to-late-stage clinical programs in multiple therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-upcoming-healthcare-conferences-301672091.html
SOURCE Neurocrine Biosciences, Inc.
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Neurocrine Biosciences Inc.mehr Nachrichten
10.02.25 |
Starker Wochentag in New York: NASDAQ Composite verbucht am Mittag Gewinne (finanzen.at) | |
07.02.25 |
Verluste in New York: NASDAQ Composite schließt mit Verlusten (finanzen.at) | |
07.02.25 |
Schwache Performance in New York: So entwickelt sich der NASDAQ Composite aktuell (finanzen.at) | |
07.02.25 |
Schwacher Handel in New York: So bewegt sich der NASDAQ Composite mittags (finanzen.at) | |
07.02.25 |
Börse New York in Rot: NASDAQ Composite gibt zum Handelsstart nach (finanzen.at) | |
07.02.25 |
NASDAQ Composite Index-Wert Neurocrine Biosciences-Aktie: So viel Gewinn hätte eine Neurocrine Biosciences-Investition von vor 3 Jahren eingebracht (finanzen.at) | |
05.02.25 |
Ausblick: Neurocrine Biosciences veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net) | |
31.01.25 |
NASDAQ Composite Index-Titel Neurocrine Biosciences-Aktie: So viel hätten Anleger mit einem Investment in Neurocrine Biosciences von vor einem Jahr verdient (finanzen.at) |
Analysen zu Neurocrine Biosciences Inc.mehr Analysen
Aktien in diesem Artikel
Neurocrine Biosciences Inc. | 110,10 | -2,18% |
|